Angiomax Drug maker Medicines Co. have announced that they have filed lawsuits in the U.S. District Court for the District of Delaware against Teva Pharmaceutical Laboratories Inc. and Pliva Hrvatsk following their submissions to the U.S. Food and Drug Administration to approve a generic version of the company’s anti-clotting agent Angiomax.
Dr Michael Factor is a leading Israel Patent and Trademark Attorney. For queries regarding filing and prosecuting patents in Israel contact Dr. Factor on mfactor @ ipfactor.co.il.